Translational Breast Cancer Research最新文献_第7页

A review of endocrine therapy in early estrogen receptor-positive breast cancer by St. Gallen Breast Cancer Conference 2021 2021年圣加仑乳腺癌会议对早期雌激素受体阳性乳腺癌内分泌治疗的回顾

Translational Breast Cancer Research Pub Date : 2021-07-01 DOI: 10.21037/TBCR-21-11

Y. Zhou, Jin Yang

{"title":"A review of endocrine therapy in early estrogen receptor-positive breast cancer by St. Gallen Breast Cancer Conference 2021","authors":"Y. Zhou, Jin Yang","doi":"10.21037/TBCR-21-11","DOIUrl":"https://doi.org/10.21037/TBCR-21-11","url":null,"abstract":"Estrogen receptor (ER) positive (+) breast cancer is heterogeneous; thus, corresponding therapeutic regimens must differ according to the individual characteristics of ER+ breast cancer patients. At the 17th international St. Gallen Breast Cancer Conference (SG-BCC) in 2021, experts voted on numerous critical issues in relation to the use of neoadjuvant endocrine therapy (NET) and adjuvant endocrine therapy (AET) in the treatment of ER+ breast cancer. We interpreted the critical issues related to NET and AET according to the voting results of the 2021 SG-BCC and clinical practice in China. Specifically, we considered the following 8 points: (I) the selection of prognostic indicators for NET; (II) the selection of a NET population based on Ki-67; (III) the selection of polygenic testing combined with Ki-67 in the exemption of neoadjuvant chemotherapy; (IV) the selection of an AET population based on ER expression level and tumor size; (V) the selection of ovarian function suppression for a premenopausal population; (VI) the selection of early stage intensive AET for a postmenopausal population; (VII) the selection of an extended AET population; and (VIII) the selection of individuals exempt from chemotherapy. We combined the results of existing clinical studies to analyze the reasons why the experts at the 2021 SG-BCC voted on the above issues, and how clinicians should use the voting results of the 2021 SG-BCC poll to select therapeutic regimens for patients. Decisions to use ET to treat ER+ breast cancer patients should always balance individualized therapy and standardized therapy.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121820004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing HER2-positive breast cancer therapy through neoadjuvant platforms: controversies and concepts 通过新辅助平台优化her2阳性乳腺癌治疗:争议和概念

Translational Breast Cancer Research Pub Date : 2021-07-01 DOI: 10.21037/TBCR-21-10

Shuang-Ling Wu, Ying-Ying Xu

{"title":"Optimizing HER2-positive breast cancer therapy through neoadjuvant platforms: controversies and concepts","authors":"Shuang-Ling Wu, Ying-Ying Xu","doi":"10.21037/TBCR-21-10","DOIUrl":"https://doi.org/10.21037/TBCR-21-10","url":null,"abstract":": HER2-positive breast cancer is a highly aggressive subtype that once had a poor prognosis. While the last two decades have seen progress in multiple HER2-targeting agents that lead to improved patient outcomes, these benefits are accompanied by increased toxicity and great cost. In addition, as not all patients have the same risk of disease, individualized treatment regimens are required. Neoadjuvant therapy can allow surgical de-escalation while also providing efficacy and prognostic information, and for HER2-positive breast cancer, chemotherapy combined with dual HER2-blockade regimens can achieve 42−68% pathologic complete response (pCR) and translate to excellent outcomes. The KATHERINE study showed that adjuvant trastuzumab emtansine (T-DM1) ameliorated invasive disease-free survival (iDFS) significantly in patients with residual disease. However, the question remains as to whether treatment can be tailored for patients with pCR or early response, and several ongoing trials such as CompassHER2 and PHERGain are attempting to address this. Preoperative therapy is currently recommended by the American National Comprehensive Cancer Network (NCCN) and by Chinese Guidelines for HER2-positive breast cancer patients with ≥ T2 or ≥ N1. For now, we can call neoadjuvant therapy a promising platform for optimizing HER2-positive breast cancer treatment. However, it is an ongoing challenge to individualize management of anti-HER2 regimens, and this narrative review will discuss current trials and comment on several controversial topics based on therapeutic strategies and clinical practices in China.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126997252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case report of primary squamous cell carcinoma of the breast 原发性乳腺鳞状细胞癌1例报告

Translational Breast Cancer Research Pub Date : 2021-04-30 DOI: 10.21037/TBCR-20-67

Xiao-Xiao Yao, Huihua He, Jingping Yuan, F. Yao

{"title":"A case report of primary squamous cell carcinoma of the breast","authors":"Xiao-Xiao Yao, Huihua He, Jingping Yuan, F. Yao","doi":"10.21037/TBCR-20-67","DOIUrl":"https://doi.org/10.21037/TBCR-20-67","url":null,"abstract":": Primary squamous cell carcinoma (SCC) of the breast is a metaplastic carcinoma subtype and an especially aggressive tumor with poor prognosis. Here, we present a case of locally advanced primary SCC of the breast. We reported a case of a 32-year-old woman with a palpable lump in the inner quadrant of the right breast. Core needle biopsy was performed and revealed SCC. Immunohistochemistry staining indicated that the patient had estrogen receptor (ER)-positive immunoreactivity, but was negative for both progesterone receptor and human epidermal growth factor receptor 2 (HER2). Magnetic resonance imaging (MRI) found a mass in the right breast just 4.8 cm × 4.3 cm × 3.4 cm in size. We planned neoadjuvant chemotherapy consisting of 4 cycle of nab-paclitaxel and every 3 weeks followed by 4 cycles of epirubicin and cyclophosphamide (EC) every 2 weeks. However, after 3 cycles of EC, the disease progressed, and the chemotherapy agents were switched to nab-paclitaxel and cisplatin. Still, disease progression continued, and the chemotherapy agents were changed once more to apatinib, eribulin, and camrelizumab. As this also did not work, modified radical mastectomy was performed. Postoperative pathology revealed extensive necrosis. Our case did not achieve pathologic complete response after neoadjuvant chemotherapy. We then started local radiotherapy, and then adjuvant tamoxifen treatment of 20 mg/day followed by 6 cycles of capecitabine. No evidence of disease was detected at half-year follow-up.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131031858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of FOXP3 of interstitial tissue in the pathogenesis of breast cancer 间质组织FOXP3在乳腺癌发病机制中的作用

Translational Breast Cancer Research Pub Date : 2021-04-30 DOI: 10.21037/TBCR-21-1

Yu-juan Xiang, Man Feng, Liyuan Liu, Fei Wang, Li-xiang Yu, Fei Zhou, Shuya Huang, Chao Zheng, C. Ye, Wen-zhong Zhou, G. Yin, Zhong-bing Ma, Liang Li, Qiang Zhang, Qin-ye Fu, Zhigang Yu

{"title":"The role of FOXP3 of interstitial tissue in the pathogenesis of breast cancer","authors":"Yu-juan Xiang, Man Feng, Liyuan Liu, Fei Wang, Li-xiang Yu, Fei Zhou, Shuya Huang, Chao Zheng, C. Ye, Wen-zhong Zhou, G. Yin, Zhong-bing Ma, Liang Li, Qiang Zhang, Qin-ye Fu, Zhigang Yu","doi":"10.21037/TBCR-21-1","DOIUrl":"https://doi.org/10.21037/TBCR-21-1","url":null,"abstract":"Background: The study aimed to evaluate the expression level of FOXP3 and the degree of FOXP3 positive lymphocytes in the interstitial tissues of normal breast tissues, primary breast cancer tissues and axillary lymph node metastatic cancer tissues, so as to better clarify FOXP3’s role in the process of breast cancer tumorigenesis and progression. Methods: FOXP3 protein expression and FOXP3 positive tumor infiltrating lymphocytes were investigated by immunohistochemistry analysis in normal breast tissues, primary breast cancer tissues and axillary lymph node metastatic cancer tissues achieved from 44 patients. Results: Compared to normal breast tissues, the expression of FOXP3 in interstitial tissues in primary and metastatic cancer tissues was significantly up-regulated. The FOXP3 positive lymphocytes infiltrated interstitial tissues in 30 of 44 (68.2%) specimens of normal breast tissues, 40 of 44 (90.9%) specimens of primary cancer tissues and 42 of 44 (95.5%) specimens of axillary lymph node metastatic cancer tissues. There was linear correlation trend between FOXP3 expression and the process transforming from normal breast epithelium to primary cancer and metastatic cancer, indicating its potential role in the pathogenesis of this disease. And we found that the expression of interstitial FOXP3 in axillary lymph node metastatic cancer site was correlated with the lymph node ratio (LNR), and LNR was higher in the FOXP3 positive expression group than the FOXP3 absent group. Conclusions: Increased FOXP3 expression in cancer interstitial tissues and FOXP3 positive lymphocytes infiltration might have a certain correlation with the development of breast cancer through facilitating immune escape of tumor.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128598247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DESTINY-Breast01 Trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer DESTINY-Breast01试验:曲妥珠单抗deruxtecan治疗先前治疗的HER2阳性乳腺癌

Translational Breast Cancer Research Pub Date : 2021-01-01 DOI: 10.21037/tbcr-21-20

E. B. Jackson, C. Simmons, K. Gelmon

引用次数: 2

Role of abemaciclib in primary breast cancer: a narrative review of MonarchE abemaciclib在原发性乳腺癌中的作用:MonarchE的叙述性回顾

Translational Breast Cancer Research Pub Date : 2021-01-01 DOI: 10.21037/tbcr-21-27

N. Takahashi, C. Shimizu, A. Shimomura, M. Toi

引用次数: 0

CDK4/6 inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer CDK4/6抑制剂联合氟维司汀治疗HR+/HER2−晚期乳腺癌

Translational Breast Cancer Research Pub Date : 2021-01-01 DOI: 10.21037/tbcr-22-17

J. Zhang, Chun-fang Hao

引用次数: 0

Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer 晚期三阴性乳腺癌治疗现状及建议的叙述性综述

Translational Breast Cancer Research Pub Date : 2021-01-01 DOI: 10.21037/tbcr-22-12

Y. Zhou, J. Yang

引用次数: 0

Escalating and de-escalating treatments in HR+HER2− early-stage breast cancer HR+HER2−早期乳腺癌的升级和降级治疗

Translational Breast Cancer Research Pub Date : 2021-01-01 DOI: 10.21037/tbcr-22-20

R. Ge

引用次数: 1

A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer her2靶向抗体药物偶联物治疗晚期乳腺癌的现状和未来展望

Translational Breast Cancer Research Pub Date : 2021-01-01 DOI: 10.21037/tbcr-21-22

Hu Li, Hongfeng Li

引用次数: 1